Literature DB >> 2609937

Gliosarcoma: an immunohistochemical study.

J W Grant1, P V Steart, A Aguzzi, D B Jones, P J Gallagher.   

Abstract

Gliosarcomas contain both neuro-ectodermal and mesenchymal elements. Its histogenesis has been much debated and endothelial and adventitial fibroblast origins have been suggested, as has a "histiocytic" origin following the demonstration of antiprotease activity. Eight gliosarcomas have been examined with a panel of ten monoclonal and polyclonal antibodies to investigate the origin of the sarcomatous element. Glial fibrillary acid protein expression showed a sharp distinction between gliomatous and sarcomatous tumour components. Contrary to some previous reports factor 8-related antigen and Ulex europeus agglutinin stained vascular luminal endothelium but no tumour cells. Vimentin and fibronectin expression was extensive and confined largely to sarcomatous areas. Desmin and neurofilament protein could not be demonstrated in any of the cases. Numerous cells, particularly in the sarcoma areas, expressed alpha-1-antitrypsin and -chymotrypsin. A proportion of these stained for the monocyte/macrophage marker MAC 387. Four cases focally exhibited a true storiform pattern and this and the immunohistochemical results suggest analogies with the fibrous histiocytomas. These tumours contain reactive histiocytes but are now thought to be derived from fibroblasts or from pluripotent mesenchymal cells in perivascular adventitia. This resembles the pattern exhibited in the sarcomatous component of gliosarcomas.

Entities:  

Mesh:

Year:  1989        PMID: 2609937     DOI: 10.1007/bf00294666

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  33 in total

1.  Establishment and characterization of neoplastic cells from a malignant fibrous histiocytoma. A possible stem cell line.

Authors:  K Shirasuna; M Sugiyama; T Miyazaki
Journal:  Cancer       Date:  1985-06-01       Impact factor: 6.860

2.  The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique.

Authors:  B L Mepham; W Frater; B S Mitchell
Journal:  Histochem J       Date:  1979-05

3.  Malignant fibrous histiocytoma tumor cells resemble fibroblasts.

Authors:  G S Wood; J H Beckstead; R R Turner; M R Hendrickson; R L Kempson; R A Warnke
Journal:  Am J Surg Pathol       Date:  1986-05       Impact factor: 6.394

4.  Clinical and pathological study of 24 cases of gliosarcoma.

Authors:  R A Morantz; I Feigin; J Ransohoff
Journal:  J Neurosurg       Date:  1976-10       Impact factor: 5.115

5.  Immunohistochemical observation of intracytoplasmic lysozyme in proliferative and neoplastic fibrohistiocytic lesions.

Authors:  S Nakanishi; S Shinomiya; T Sano; K Hizawa
Journal:  Acta Pathol Jpn       Date:  1982-11

6.  Immunohistochemical investigations of tumors of supposed fibroblastic-histiocytic origin.

Authors:  L G Kindblom; G K Jacobsen; M Jacobsen
Journal:  Hum Pathol       Date:  1982-09       Impact factor: 3.466

7.  Immunohistological study on malignant fibrous histiocytoma.

Authors:  A Inoue; K Aozasa; M Tsujimoto; M Tamai; F Chatani; H Ueno
Journal:  Acta Pathol Jpn       Date:  1984-07

8.  Immunohistochemical demonstration of alpha-1-proteinase inhibitor in brain tumors.

Authors:  M Zuccarello; R Sawaya; M B Ray
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

9.  Factor VII related antigen as an endothelial cell marker in benign and malignant diseases.

Authors:  M Sehested; K Hou-Jensen
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

Review 10.  Anti-alpha 1-antichymotrypsin staining of 194 sarcomas, 38 carcinomas, and 17 malignant melanomas. Its lack of specificity as a tumour marker.

Authors:  M Leader; J Patel; M Collins; K Henry
Journal:  Am J Surg Pathol       Date:  1987-02       Impact factor: 6.394

View more
  15 in total

1.  Sarcomatous proliferation of the vasculature in a subependymoma: a follow-up study of sarcomatous dedifferentiation.

Authors:  D N Louis; E T Hedley-Whyte; R L Martuza
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Gliofibroma: immunohistochemical analysis.

Authors:  R Schober; C Bayindir; A Canbolat; H Urich; W Wechsler
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Histogenesis of sarcomatous component of the gliosarcoma: an ultrastructural study.

Authors:  K L Ho
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

4.  Genetic profile of gliosarcomas.

Authors:  R M Reis; D Könü-Lebleblicioglu; J M Lopes; P Kleihues; H Ohgaki
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line.

Authors:  Pei-Sen Yao; De-Zhi Kang; Xing-Fu Wang; Ru-Ying Lin; Zu-Cheng Ye
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-12-25       Impact factor: 2.416

6.  Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms. A light microscopic and immunohistochemical study of formalin-fixed, routinely processed material.

Authors:  P Wesseling; J J Vandersteenhoven; B T Downey; D J Ruiter; P C Burger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis.

Authors:  M Higuchi; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 8.  Gliofibromas (including malignant forms), and gliosarcomas: a comparative study and review of the literature.

Authors:  M Cerda-Nicolas; J J Kepes
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Distribution of p53 protein expression in gliosarcomas: an immunohistochemical study.

Authors:  S Albrecht; J H Connelly; J M Bruner
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 10.  Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity.

Authors:  Seunggu J Han; Isaac Yang; Tarik Tihan; Michael D Prados; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-07-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.